News | January 13, 2012

FDA Releases Preliminary Findings From Ongoing CardioGen-82 Investigations

January 13, 2012 – The U.S. Food and Drug Administration (FDA) is updating healthcare professionals and the public about preliminary findings from ongoing investigations following the voluntary recall of CardioGen-82 last July by the manufacturer, Bracco Diagnostics. CardioGen-82 consists of a generator that is used at clinical sites to produce rubidium (Rb)-82 chloride injection. A CardioGen-82 positron emission tomography (PET) scan is one of a variety of nuclear medicine scans that use radioactive drugs to evaluate myocardial perfusion.

The preliminary information from the investigations suggests that improper usage of CardioGen-82 at certain clinical sites is responsible for the exposure of some patients to more radiation than is typically associated with a CardioGen-82 scan. This increased radiation exposure was due to the administration of CardioGen-82 generator eluates that contained excessive concentrations of strontium-82 (Sr-82) and strontium-85 (Sr-85). This excessive release of Sr-82 and Sr-85 in generator eluates is known as "strontium breakthrough." FDA believes it is unlikely that this excessive exposure posed significant risks to patients, though exposure to any excessive radiation is undesirable.

In its July 26, 2011 Drug Safety Communication, the FDA said it indentified deficiencies with the manufacturing procedures for CardioGen-82. To date, these deficiencies do not appear to have been related to the excessive radiation exposure detected in some patients. The recalled CardioGen-82 generators that were functional following shipping were tested by the manufacturer to identify potential structural or functional causes of strontium breakthrough. None of the tested generators showed signs of breakthrough. The FDA said it continues to work with the manufacturer to resolve their manufacturing deficiencies.

Bracco is currently conducting studies of clinical sites across the nation to help assess the extent to which patients may have been exposed to excessive radiation. Participation in this study is voluntary and the preliminary data show that, of 375 patients who were surveyed at 43 clinical sites, 54 patients were planned for further radiation testing because of abnormal screening test results. All 54 patients are from two clinical sites. Both sites appear to have insufficient documentation of compliance with the CardioGen-82 labeling recommendations for strontium breakthrough testing.

The FDA continues to work with the manufacturer and other federal agencies to better characterize the problems that led to excessive radiation exposure to patients at certain clinical sites. FDA is also working with the manufacturer to revise the CardioGen-82 labeling to better describe how to use the generator and to implement a plan for the return of CardioGen-82 to the market. FDA will update the public when additional information becomes available.

For more information: www.cardiogen.com, www.nrc.gov

Related Content

Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017
In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
cardiac PET, myocardial perfusion, PET-CT, cardiac perfusion

A PET-CT cardiac perfusion exam from a Siemens Biograph scanner. The black and white areas of the image show the CT imaging of the anatomy. The colored portion shows the PET overlay on the myocardium and is color-coded to show tracer uptake values. This can show areas of the heart muscle where there are perfusion defects cause by infarcts or coronary artery blockages due to a heart attack and help determine the severity of the ischemia.

Feature | PET Imaging | June 03, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging | September 23, 2015
September 23, 2015 — New research de
Overlay Init